Intravenous vs Oral Acetaminophen in Postoperative Hip Fracture Adult Patients

NCT ID: NCT05425355

Last Updated: 2025-05-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE4

Total Enrollment

42 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-01-23

Study Completion Date

2026-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The INTACT-HIP trial study will evaluate feasibility of conducting a randomized, double-blinded controlled trial comparing postoperative treatment with intravenous (IV) acetaminophen versus oral acetaminophen, in older adults undergoing hip fracture surgery.

The results of this feasibility trial will be used to inform designing a larger, multi-center, randomized controlled trial to assess the efficacy of IV acetaminophen compared to oral acetaminophen to reduce delirium and improve other clinical and patient-centered outcomes after hip fracture surgery. It will randomize 42 older adults to receive either oral or IV acetaminophen after hip fracture surgery.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hip-fracture Surgery

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

The study intervention will start after the surgery for the hip fracture with administration of the study drugs, starting in the post-anesthesia care unit (PACU). All patients will receive both a tablet and an IV solution every 6 hours for 48 hours, for a total of 8 doses. In the intravenous (IV) group, the IV study drug will be IV acetaminophen and the oral study drug will be a placebo tablet; vice versa, in the per oral (PO) group, the IV study drug will be normal saline and the pill will be acetaminophen. After 48 hours, all the patients will receive oral acetaminophen every 6 hours as per usual practice
Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors
Quadruple blinded

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intravenous (IV) acetaminophen plus oral placebo

In this group, the IV study drug will be IV acetaminophen and the oral study drug will be a placebo tablet.

Group Type EXPERIMENTAL

Intravenous (IV) acetaminophen + oral placebo

Intervention Type DRUG

Postoperatively patients will receive both a tablet and an IV solution every 6 hours for 48 hours, for a total of 8 doses. In this group, the IV study drug will be IV acetaminophen and the oral study drug will be a placebo tablet.

Intravenous (IV) placebo plus oral acetaminophen

In this group the IV study drug will be normal saline and the pill will be acetaminophen

Group Type ACTIVE_COMPARATOR

Intravenous (IV) placebo plus oral acetaminophen

Intervention Type DRUG

Postoperatively patients will receive both a tablet and an IV solution every 6 hours for 48 hours, for a total of 8 doses. In this group the IV study drug will be normal saline and the pill will be acetaminophen

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Intravenous (IV) acetaminophen + oral placebo

Postoperatively patients will receive both a tablet and an IV solution every 6 hours for 48 hours, for a total of 8 doses. In this group, the IV study drug will be IV acetaminophen and the oral study drug will be a placebo tablet.

Intervention Type DRUG

Intravenous (IV) placebo plus oral acetaminophen

Postoperatively patients will receive both a tablet and an IV solution every 6 hours for 48 hours, for a total of 8 doses. In this group the IV study drug will be normal saline and the pill will be acetaminophen

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 60 years of age and older
* Patients who were ambulating without human assistance before fracture, with any type of non-neoplastic hip fracture
* Patients undergoing surgical treatment as an inpatient

Exclusion Criteria

* Patients with neoplastic hip fracture
* Severe cognitive impairment (Montreal Cognitive Assessment (MoCA) \<10)
* Pre-existing delirium
* Known hypersensitivity or allergy to acetaminophen
* Severe or chronic liver or kidney dysfunction
* Planned postoperative ventilation
* Swallowing issues and/or dysphagia
* English language limitation
* Weight \<50kg
Minimum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Health Network, Toronto

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jean Wong

Associate Professor, University of Toronto, Department of Anesthesiology and Pain Medicine

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jean Wong, MD

Role: PRINCIPAL_INVESTIGATOR

University Health Network, Toronto

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Toronto Western Hospital (UHN)

Toronto, Ontario, Canada

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Canada

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Laurentia Enesi

Role: CONTACT

416-603-5800 ext. 3959

Aparna P Saripella

Role: CONTACT

416-603-5800 ext. 6137

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Dr. Jean Wong, MD

Role: primary

Dr.Simone Schiavo, MD

Role: backup

References

Explore related publications, articles, or registry entries linked to this study.

Jahr JS, Breitmeyer JB, Pan C, Royal MA, Ang RY. Safety and efficacy of intravenous acetaminophen in the elderly after major orthopedic surgery: subset data analysis from 3, randomized, placebo-controlled trials. Am J Ther. 2012 Mar;19(2):66-75. doi: 10.1097/MJT.0b013e3182456810.

Reference Type RESULT
PMID: 22354127 (View on PubMed)

Chen DX, Yang L, Ding L, Li SY, Qi YN, Li Q. Perioperative outcomes in geriatric patients undergoing hip fracture surgery with different anesthesia techniques: A systematic review and meta-analysis. Medicine (Baltimore). 2019 Dec;98(49):e18220. doi: 10.1097/MD.0000000000018220.

Reference Type RESULT
PMID: 31804347 (View on PubMed)

Harris MJ, Brovman EY, Urman RD. Clinical predictors of postoperative delirium, functional status, and mortality in geriatric patients undergoing non-elective surgery for hip fracture. J Clin Anesth. 2019 Dec;58:61-71. doi: 10.1016/j.jclinane.2019.05.010. Epub 2019 May 14.

Reference Type RESULT
PMID: 31100691 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

21-5733

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

The Stronger at Home Study
NCT04228068 COMPLETED NA